Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.
Identifieur interne : 000B14 ( Main/Corpus ); précédent : 000B13; suivant : 000B15Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.
Auteurs : Giovanni Tommaso Ranaldi ; Emanuele Rocco Villani ; Laura FranzaSource :
- Medical gas research [ 2045-9912 ]
English descriptors
- KwdEn :
- Betacoronavirus (isolation & purification), COVID-19 (MeSH), Combined Modality Therapy (MeSH), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Humans (MeSH), Ozone (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Ozone.
- isolation & purification : Betacoronavirus.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Combined Modality Therapy, Humans, Pandemics, SARS-CoV-2, Treatment Outcome.
Abstract
Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such as heparin and low molecular weight heparin, are currently being administered with some benefit. Ozone therapy consists in the administration of a mixture of ozone and oxygen, called medical ozone, which has been used for over a century as an unconventional medicine practice for several diseases. Medical ozone rationale in COVID-19 is the possibility of contrasting endothelial dysfunction, modulating the immune response and acting as a virustatic agent. Thus, medical ozone could help to decrease lung inflammation, slow down viral growth, regulate lung circulation and oxygenation and prevent microvascular thrombosis. Ozone-therapy could be considered a feasible, cost-effective and easy to administer adjuvant therapy while waiting for the synthesis of a therapy or the development of the vaccine.
DOI: 10.4103/2045-9912.289462
PubMed: 33004712
PubMed Central: PMC8086623
Links to Exploration step
pubmed:33004712Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.</title>
<author><name sortKey="Ranaldi, Giovanni Tommaso" sort="Ranaldi, Giovanni Tommaso" uniqKey="Ranaldi G" first="Giovanni Tommaso" last="Ranaldi">Giovanni Tommaso Ranaldi</name>
<affiliation><nlm:affiliation>Unità Operativa Semplice Dipartimentale Farmacologia Clinica e Sperimentazione Clinica, Azienda Sanitaria, Potenza, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Villani, Emanuele Rocco" sort="Villani, Emanuele Rocco" uniqKey="Villani E" first="Emanuele Rocco" last="Villani">Emanuele Rocco Villani</name>
<affiliation><nlm:affiliation>Department of Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Franza, Laura" sort="Franza, Laura" uniqKey="Franza L" first="Laura" last="Franza">Laura Franza</name>
<affiliation><nlm:affiliation>Department of Emergency Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 Jul-Sep</date>
<idno type="RBID">pubmed:33004712</idno>
<idno type="pmid">33004712</idno>
<idno type="doi">10.4103/2045-9912.289462</idno>
<idno type="pmc">PMC8086623</idno>
<idno type="wicri:Area/Main/Corpus">000B14</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.</title>
<author><name sortKey="Ranaldi, Giovanni Tommaso" sort="Ranaldi, Giovanni Tommaso" uniqKey="Ranaldi G" first="Giovanni Tommaso" last="Ranaldi">Giovanni Tommaso Ranaldi</name>
<affiliation><nlm:affiliation>Unità Operativa Semplice Dipartimentale Farmacologia Clinica e Sperimentazione Clinica, Azienda Sanitaria, Potenza, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Villani, Emanuele Rocco" sort="Villani, Emanuele Rocco" uniqKey="Villani E" first="Emanuele Rocco" last="Villani">Emanuele Rocco Villani</name>
<affiliation><nlm:affiliation>Department of Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Franza, Laura" sort="Franza, Laura" uniqKey="Franza L" first="Laura" last="Franza">Laura Franza</name>
<affiliation><nlm:affiliation>Department of Emergency Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Medical gas research</title>
<idno type="eISSN">2045-9912</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (isolation & purification)</term>
<term>COVID-19 (MeSH)</term>
<term>Combined Modality Therapy (MeSH)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans (MeSH)</term>
<term>Ozone (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ozone</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Combined Modality Therapy</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such as heparin and low molecular weight heparin, are currently being administered with some benefit. Ozone therapy consists in the administration of a mixture of ozone and oxygen, called medical ozone, which has been used for over a century as an unconventional medicine practice for several diseases. Medical ozone rationale in COVID-19 is the possibility of contrasting endothelial dysfunction, modulating the immune response and acting as a virustatic agent. Thus, medical ozone could help to decrease lung inflammation, slow down viral growth, regulate lung circulation and oxygenation and prevent microvascular thrombosis. Ozone-therapy could be considered a feasible, cost-effective and easy to administer adjuvant therapy while waiting for the synthesis of a therapy or the development of the vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33004712</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2045-9912</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<Issue>3</Issue>
<PubDate><MedlineDate>2020 Jul-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Medical gas research</Title>
<ISOAbbreviation>Med Gas Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.</ArticleTitle>
<Pagination><MedlinePgn>134-138</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2045-9912.289462</ELocationID>
<Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) is the respiratory disease caused by the novel severe acute respiratory syndrome-coronavirus-2 and is characterized by clinical manifestations ranging from mild, flu-like symptoms to severe respiratory insufficiency and multi-organ failure. Patients with more severe symptoms may require intensive care treatments and face a high mortality risk. Also, thrombotic complications such as pulmonary embolisms and disseminated intravascular coagulation are frequent in these patients. Indeed, COVID-19 is characterized by an abnormal inflammatory response resembling a cytokine storm, which is associated to endothelial dysfunction and microvascular complications. To date, no specific treatments are available for COVID-19 and its life-threatening complication. Immunomodulatory drugs, such as hydroxychloroquine and interleukin-6 inhibitors, as well as antithrombotic drugs such as heparin and low molecular weight heparin, are currently being administered with some benefit. Ozone therapy consists in the administration of a mixture of ozone and oxygen, called medical ozone, which has been used for over a century as an unconventional medicine practice for several diseases. Medical ozone rationale in COVID-19 is the possibility of contrasting endothelial dysfunction, modulating the immune response and acting as a virustatic agent. Thus, medical ozone could help to decrease lung inflammation, slow down viral growth, regulate lung circulation and oxygenation and prevent microvascular thrombosis. Ozone-therapy could be considered a feasible, cost-effective and easy to administer adjuvant therapy while waiting for the synthesis of a therapy or the development of the vaccine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ranaldi</LastName>
<ForeName>Giovanni Tommaso</ForeName>
<Initials>GT</Initials>
<AffiliationInfo><Affiliation>Unità Operativa Semplice Dipartimentale Farmacologia Clinica e Sperimentazione Clinica, Azienda Sanitaria, Potenza, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Villani</LastName>
<ForeName>Emanuele Rocco</ForeName>
<Initials>ER</Initials>
<AffiliationInfo><Affiliation>Department of Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Franza</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Emergency Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Australia</Country>
<MedlineTA>Med Gas Res</MedlineTA>
<NlmUniqueID>101564536</NlmUniqueID>
<ISSNLinking>2045-9912</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>66H7ZZK23N</RegistryNumber>
<NameOfSubstance UI="D010126">Ozone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010126" MajorTopicYN="N">Ozone</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">SARS-COV-2</Keyword>
<Keyword MajorTopicYN="Y">cytokine storm</Keyword>
<Keyword MajorTopicYN="Y">endothelial dysfunction</Keyword>
<Keyword MajorTopicYN="Y">immunomodulation</Keyword>
<Keyword MajorTopicYN="Y">medical ozone</Keyword>
<Keyword MajorTopicYN="Y">ozone</Keyword>
<Keyword MajorTopicYN="Y">ozone therapy</Keyword>
<Keyword MajorTopicYN="Y">virustatic</Keyword>
</KeywordList>
<CoiStatement>None</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>5</Hour>
<Minute>36</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33004712</ArticleId>
<ArticleId IdType="pii">MedGasRes_2020_10_3_134_289462</ArticleId>
<ArticleId IdType="doi">10.4103/2045-9912.289462</ArticleId>
<ArticleId IdType="pmc">PMC8086623</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Liver Int. 2020 Sep;40(9):2095-2103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32239796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Virol. 2016 Sep 29;3(1):237-261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27578435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Metab. 2018 Aug;14:71-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29914852</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Jun 2;172(11):754-755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32232419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Jul;18(7):1752-1755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32267998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesthesiol Intensive Ther. 2016;48(4):261-265</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27660252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brain Behav Immun. 2020 Jul;87:18-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesth Crit Care Pain Med. 2020 Jun;39(3):389-390</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Environ Health. 1979 Sep-Oct;34(5):346-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">496433</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2014 Nov 5;742:158-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25218903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 2019 Sep-Oct;33(5):1321-1326</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31663301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Med Sci. 2011 Jan 03;8(1):48-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21234269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2019 Jun 6;15(6):e1007795</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31170267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 26;382(13):1199-1207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31995857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Obes Metab. 2015 May;17(5):435-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25469642</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Gas Res. 2020 Apr-Jun;10(2):61-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32541128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Gastroenterol. 2010 May 05;10:42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20444253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2005 May;77(5):598-625</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15689384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1574-1581</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mediators Inflamm. 1998;7(5):313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9883965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19233695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 1999 Nov 15;9(22):3255-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10576698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 May;18(5):1020-1022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32239799</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Reumatol Port. 2018 Jul-Sep;43(3):210-216</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30414369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomolecules. 2018 Dec 17;8(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30563025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pol Merkur Lekarski. 2001 Aug;11(62):180-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11757225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Emerg Med. 2007 Jan;49(1):88-98, 98.e1-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17095120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1285-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19164583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2018 May 1;128(5):2064-2075</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29664014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 1997 Nov;147(1):71-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9356309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2015 Oct 27;(10):CD008474</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26505864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anaesthesiol Intensive Ther. 2020;52(1):34-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Dent Res. 2007 May;86(5):451-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17452567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Biol Macromol. 2006 Nov 15;39(4-5):317-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16712921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):400-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2016 Aug 15;305:40-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27286659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mediators Inflamm. 2005 Feb 24;2005(1):16-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15770062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Microbiol. 2016 Jul 30;16(1):173</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27475908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Thromb Hemost. 2015 Sep;41(6):659-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26305236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2019 Sep 25;14(9):e0222601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31553765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Int Med Res. 1994 May-Jun;22(3):131-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8088420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transl Res. 2020 Jun;220:1-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32299776</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Gas Res. 2017 Oct 17;7(3):212-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29152215</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Angiol. 1997 Dec;16(4):250-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9543222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AJR Am J Roentgenol. 2020 Jul;215(1):87-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32174129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Free Radic Biol Med. 1991;11(1):81-128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1937131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Korean J Intern Med. 2015 Jan;30(1):1-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Apr;92(4):424-432</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31981224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1537-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19542024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Water Res. 2019 Sep 1;160:339-349</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31158616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2001 May 15;173(1):18-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11350211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Neurol. 2020 Jun 1;77(6):683-690</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Res Rev. 2009 Jul;29(4):646-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19260079</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33004712 |texte= Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33004712" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |